Neurotoxic bilirubin is the end product of heme catabolism in mammals. Bilirubin is solely conjugated by uridine diphosphoglucuronosyltransferase 1A1, which is a membrane-bound enzyme that catalyzes the transfer of glucuronic acid. Due to low function of hepatic and intestinal uridine diphospho-glucuronosyltransferase 1A1 during the neonatal period, human neonates develop mild to severe physiological hyperbilirubinemia. Accumulation of bilirubin in the brain leads to the onset of irreversible brain damage, termed kernicterus. Breastfeeding is one of the most significant factors that increase the risk of developing kernicterus in infants. Why does this most natural way of feeding increase the risk of brain damage or even death? This question leads to the hypothesis that breast milk-induced hyperbilirubinemia might bring certain benefits that outweigh those risks. While bilirubin is neurotoxic and cytotoxic, this compound is also a potent antioxidant. There are studies showing improved clinical conditions in patients with hyperbilirubinemia. Accumulating evidence also shows that genetic polymorphisms linked to hyperbilirubinemia are beneficial against various diseases. In this review article, we first introduce the production, metabolism, and transport of bilirubin. We then discuss the potential benefits of neonatal and adult hyperbilirubinemia. Finally, epigenetic factors as well as metabolomic information associated with hyperbilirubinemia are described. This review article advances the understanding of the physiological importance of the paradoxical compound bilirubin. (HEPATOLOGY 2018;67:1609-1619 P roduction of bilirubin from heme catabolism is unique to mammals.
Neurotoxic bilirubin is the end product of heme catabolism in mammals. Bilirubin is solely conjugated by uridine diphosphoglucuronosyltransferase 1A1, which is a membrane-bound enzyme that catalyzes the transfer of glucuronic acid. Due to low function of hepatic and intestinal uridine diphospho-glucuronosyltransferase 1A1 during the neonatal period, human neonates develop mild to severe physiological hyperbilirubinemia. Accumulation of bilirubin in the brain leads to the onset of irreversible brain damage, termed kernicterus. Breastfeeding is one of the most significant factors that increase the risk of developing kernicterus in infants. Why does this most natural way of feeding increase the risk of brain damage or even death? This question leads to the hypothesis that breast milk-induced hyperbilirubinemia might bring certain benefits that outweigh those risks. While bilirubin is neurotoxic and cytotoxic, this compound is also a potent antioxidant. There are studies showing improved clinical conditions in patients with hyperbilirubinemia. Accumulating evidence also shows that genetic polymorphisms linked to hyperbilirubinemia are beneficial against various diseases. In this review article, we first introduce the production, metabolism, and transport of bilirubin. We then discuss the potential benefits of neonatal and adult hyperbilirubinemia. Finally, epigenetic factors as well as metabolomic information associated with hyperbilirubinemia are described. This review article advances the understanding of the physiological importance of the paradoxical compound bilirubin. (HEPATOLOGY 2018;67:1609-1619) P roduction of bilirubin from heme catabolism is unique to mammals.
(1) Even without diseases, humans physiologically develop slight hyperbilirubinemia as normal serum bilirubin levels range from 0.2 to 1.2 mg/dL, while serum bilirubin levels in other mammals are generally extremely low. In particular, human neonates physiologically develop mild to severe hyperbilirubinemia with serum bilirubin levels of approximately 5-15 mg/dL. (2) Significantly elevated serum bilirubin levels allow the invasion of bilirubin into the brain, causing irreversible brain damage, termed kernicterus. (2) The elevation of bilirubin during the neonatal period is mainly attributed to the inadequate function of bilirubinmetabolizing enzymes. (3) To prevent the development of kernicterus, human neonates with higher serum bilirubin levels commonly receive phototherapy, which nonenzymatically eliminates bilirubin in the blood. (4) Bilirubin exhibits not only neurotoxicity but also cytotoxicity in various cell types.
Is bilirubin solely a toxic compound? It has been known for more than 50 years that breast-feeding is a major factor leading to increased serum bilirubin levels in human neonates. (5) Why does this most natural way of feeding increase the risk of brain damage or even death in newborns? Despite the neurotoxicity of bilirubin, it should be noted that this compound, is also a potent antioxidant.
It has been reported that the antioxidant properties of bilirubin can be as potent as those of vitamin E or glutathione. (6) In 2004, Sedlak and Snyder demonstrated improved clinical conditions in patients with hyperbilirubinemia. (7) For example, blood antioxidant status in neonates was positively correlated with blood bilirubin levels. Risks of several diseases were much lower in patients with higher blood bilirubin levels, including coronary artery disease and amyotrophic lateral sclerosis in adults. Better outcomes were also observed in subjects with genetic polymorphisms linked to hyperbilirubinemia. These clinical observations suggest the possibility that hyperbilirubinemia brings certain benefits to human health. In this review article, we summarize the current knowledge on the regulation of bilirubin homeostasis and the potential benefits of hyperbilirubinemia. We discuss the most recent genetic and epigenetic factors linked to hyperbilirubinemia and their impact on the clinical condition as well as metabolomic changes in hyperbilirubinemia.
Production, Metabolism, and Transport of Bilirubin

CATABOLISM OF HEME
Heme consists of an Fe 21 ion in the center of porphyrin protoporphyrin-IX. Heme oxygenase-1 is an enzyme that is involved in the initial metabolism of heme. Heme oxygenase-1 metabolizes heme, producing a-hydroxyheme, a-verdoheme, ferric biliverdin, and then biliverdin. In mammals, biliverdin is further metabolized to bilirubin by biliverdin reductase. (8) 
BILIRUBIN METABOLISM
While biliverdin is hydrophilic and nontoxic, bilirubin is highly hydrophobic and toxic. The major metabolites of bilirubin are bilirubin monoglucuronides and diglucuronides, which are formed by uridine diphospho-glucuronosyltransferase (UGT) 1A1. (9) Meanwhile, bilirubin is partly converted to oxidized metabolites by cytochrome P450 (CYP) 1 and CYP2 family enzymes. (10) Although Cyp1 or Cyp2 knockout animals do not develop elevated blood bilirubin levels, humans and rodents with deleted Ugt1a1 develop severe hyperbilirubinemia, (11, 12) indicating that UGT1A1 is the rate-limiting enzyme in bilirubin metabolism (Fig.  1) . In cases of Crigler-Najjar syndrome or Gunn rats where UGT1A1 is deficient, CYP1s play a role in the compensatory pathway of bilirubin metabolism. (13, 14) 
IMPACT OF MEMBRANE TRANSPORTERS IN THE DISPOSITION OF BILIRUBUIN
Unconjugated bilirubin is selectively taken up by hepatocytes, conjugated to glucuronic acid by UGT1A1, and then secreted into bile across the canalicular membrane. (15) Because of its hydrophobic nature and high permeability through lipid bilayer membranes, unconjugated bilirubin has been suggested to cross cellular membranes by diffusion. (16) However, the selective uptake of unconjugated bilirubin into hepatocytes favors the notion that membrane transporters are involved in this process. Several lines of evidence suggest that unconjugated bilirubin is at least partially taken up into hepatocytes by members of the human organic anion-transporting polypeptide (OATP) family, particularly OATP1B1 and OATP1B3 (Fig. 1) . (17) In contrast to the debate over which membrane transporters are involved in the transport of unconjugated bilirubin, (17) there is consensus that conjugated bilirubin is taken up into hepatocytes by OATP1B1 and OATP1B3 and excreted into bile through the adenosine triphosphate-dependent efflux transporter multidrug-resistance
protein 2 (MRP2; encoded by ABCC2) (Fig. 1) . (18) Genetic variants in the ABCC2 gene leading to the absence of a functional MRP2 protein in the canalicular hepatocyte membrane are the molecular basis for Dubin-Johnson syndrome. This benign autosomal recessive disorder is characterized by conjugated hyperbilirubinemia because the lack of MRP2-mediated biliary efflux of conjugated bilirubin is compensated by its efflux into the blood through multidrug resistance-associated protein 3 located in the sinusoidal hepatocyte membrane (Fig. 1) . (18) Please see the Supporting Information.
Neonatal Hyperbilirubinemia
MOLECULAR MECHANISM OF PHYSIOLOGICAL JAUNDICE
Although mammals have a system to metabolize bilirubin in the body, human newborns physiologically develop hyperbilirubinemia. (2) In this physiological condition, serum bilirubin levels typically decrease within several weeks after birth without treatment. There are FIG. 1. Schematic representation of bilirubin homeostasis. Bilirubin, an end product of heme catabolism, is taken up into the hepatocyte, where it is glucuronidated by UGT1A1 and actively secreted into bile. Bilirubin glucuronide can be excreted or deconjugated and absorbed in the small intestine, where deconjugated bilirubin is glucuronidated again by UGT1A1. Significantly elevated serum bilirubin levels allow the entrance of bilirubin into the brain, causing irreversible brain damage, kernicterus. In contrast to the detailed knowledge on the transporters in the liver and blood-brain barrier, information on the transport of bilirubin and its glucuronide in the small intestine remains limited. Abbreviations: B, bilirubin (blue arrows); BBB, blood-brain barrier; BG, bilirubin glucuronide (orange arrows); ER, endoplasmic reticulum; MDR, multidrug-resistance protein (P-glycoprotein); MRP3, multidrug resistance-associated protein 3. two major causes of physiological jaundice in human newborns. At birth, the source of oxygenation changes from the placental circulation to gas exchange in the lungs, which is more effective. Oxidative stress derived from excessive amounts of oxygen accelerates hemolysis, resulting in the release of hemoglobin and heme from red blood cells. (19) Although the accelerated hemolysis in newborns is observed in all mammals, elevation of serum bilirubin levels is specific to human newborns, indicating that another factor must play a role.
The fact that the unconjugated form of bilirubin is observed in neonatal hyperbilirubinemia indicates that the second cause of the elevation of serum bilirubin levels in human newborns involves the metabolic process of bilirubin. Although UGT1A1 is highly expressed in the adult liver, this enzyme has been shown to be extremely limited in the developing liver. (20) This restricted function of UGT1A1 in neonatal liver is likely insufficient to clear the massive production of bilirubin within the first few days after birth in humans. Meanwhile in mice, both hepatic and intestinal UGT1A1 are highly functional even during the neonatal period, contributing to efficient metabolism and excretion of bilirubin. Humanized UGT1A1 mice can mimic human-specific neonatal jaundice, supporting the concept that the human UGT1A1 gene is primarily involved in the accumulation of unconjugated bilirubin in the blood in human newborns. (21) Surprisingly, detailed analysis revealed that gastrointestinal UGT1A1, rather than the previously hypothesized hepatic UGT1A1, largely contributes to the conjugation of bilirubin during the neonatal period ( Fig. 1 ). (21) 
KERNICTERUS
Significant increases in the amount of bilirubin in the blood allow its influx into the brain, which leads to the onset of irreversible brain damage, kernicterus. Relatively severe hyperbilirubinemia is observed in 8%-11% of human infants. (22) Approximately 1 in 1,000 infants further show total serum bilirubin values >25 mg/dL. (23) In contrast, the reported incidence of kernicterus is 1 in 50,000-100,000, which corresponds to severe hyperbilirubinemia with total serum bilirubin levels of >30 mg/dL, (24) suggesting that the threshold concentration of serum bilirubin level that leads to the onset of kernicterus is approximately 30 mg/dL in humans. To prevent the onset of kernicterus, it is recommended that human neonates with higher serum bilirubin levels receive phototherapy.
BREAST MILK-INDUCED HYPERBILIRUBINEMIA
When Winfield and MacFaul examined the incidence of jaundice in 893 newborns, of whom 55% were breast-fed, jaundice lasting for 3 weeks or more was found in 12 breast-fed babies and in no formulafed infant. (25) A recent study by Wu et al. also demonstrated that total bilirubin levels were statistically higher in the breast-fed group compared with those in the formula-fed group at both 4 and 8 weeks in 60 healthy infants. (26) The incidence of kernicterus is also higher in breast-fed infants, (27) supporting the theory that breast-feeding increases the risk of both neonatal hyperbilirubinemia and kernicterus.
There are many possible mechanisms that can explain breast milk-induced neonatal jaundice. One is the inhibition of hepatic and intestinal UGT1A1 by breast milkspecific components. (28) Other hypothetical mechanisms include increased enterohepatic circulation of bilirubin, inhibition of binding of bilirubin to serum albumin, suboptimal fluid intake, weight loss, and intestinal colonization. Nevertheless, the most recently proposed and likely mechanism is a suppression of UGT1A1 expression in the small intestine by breast milk. (3) This assumption is supported by an observation in the sole human breast milk jaundice model. (21) While UGT1A1 is highly expressed in the fetal small intestine, its expression in breast-fed pups is dramatically suppressed, causing serum bilirubin levels to rise. Expression of intestinal UGT1A1 can be restored by formula feeding, which results in accelerated bilirubin metabolism. Thus, temporary usage of formula may be beneficial for human neonates with severe hyperbilirubinemia to reduce their serum bilirubin levels and prevent kernicterus.
Please also see the Supporting Information.
Potential Benefits of Hyperbilirubinemia
IMPACT OF NEONATAL HYPERBILIRUBINEMIA
It was found that infants with oxygen radicalassociated diseases such as intraventricular hemorrhage, retinopathy, and necrotizing enterocolitis had lower levels of serum bilirubin compared to infants without such diseases. (29) Several studies described a close association between plasma bilirubin levels and plasma antioxidant capacity. (30) Jaundiced newborns had significantly lower malondialdehyde but higher superoxide dismutase, catalase, and glutathione peroxidase levels. (31) Serum total oxidant status, lipid hydroperoxide levels, and oxidative stress index levels were significantly higher after phototherapy of jaundiced infants, suggesting that either phototherapy itself or lowered serum bilirubin had a negative impact on the oxidant/antioxidant defense system, exposing infants to potential oxidative stress. (32) In 2012, significantly lower total serum bilirubin levels were found in severe retinopathy of prematurity, grade III necrotizing enterocolitis, grade III intraventricular hemorrhage, severe fungal infection, and sepsis in comparison to infants with mild or no disease. (33) These clinical findings indicate that hyperbilirubinemia increases the antioxidant capacity in blood, leading to lower oxidative stress and better outcome in free radical-associated diseases. Conversely, reduced antioxidant potency might explain the worsened retinopathy of prematurity, greater vision loss, and atopic dermatitis in infants with lower bilirubin concentrations. (34) Serum total bilirubin levels were inversely correlated with the prevalence of metabolic syndromes. (35) Puri et al. demonstrated an inverse relationship between serum bilirubin levels and the presence of nonalcoholic steatohepatitis in children with nonalcoholic fatty liver disease. (36) Serum bilirubin levels have been shown to negatively correlate to blood pressure and the body mass index score, which are well-known risk factors for metabolic syndrome. (35) These observations indicate that bilirubin has a considerable impact on metabolic function as well, possibly through antioxidant signaling. Another interesting observation is that human infants who experienced neonatal hyperbilirubinemia had a lower incidence of asthma in later life. (37) Bilirubin negatively affects the function of antigen-processing phagocytic cells, which results in the decrease or even elimination of antigenic stimulation of immunocompetent cells. (38) Therefore, neonatal hyperbilirubinemia may be a crucial event to achieve a healthy immune response (Fig. 2) .
IMPACT OF ADULT HYPERBILIRUBINEMIA
The prevalence of coronary artery disease was significantly lower in patients with hyperbilirubinemic Gilbert syndrome compared to control subjects. (39) Several other studies also demonstrated a correlation between the risk of developing coronary artery disease and decreased serum bilirubin. (40) Furthermore, the levels of unconjugated bilirubin were negatively correlated with disease activity in patients with systemic lupus erythematosus associated with increased oxidative stress. (41) Yoshino et al. demonstrated that a high bilirubin level was associated with favorable coronary endothelial function in overweight patients. (42) In a total of 690 Korean type 2 diabetes patients, total serum bilirubin concentrations were negatively associated with hemoglobin A1c levels, suggesting that hyperbilirubinemia might be a factor that can reduce the risk of developing cardiovascular disease (CVD). (43) Subjects with hyperbilirubinemia had several reduced CVD risk factors including body mass index, low-density lipoprotein, and total cholesterol. (44) A recent prospective study indicated that higher levels of serum bilirubin reduced the risk for myocardial infarction, coronary heart disease, and CVD mortality in men, (45) in agreement with a previous meta-analysis. (46) Kwak et al. also demonstrated that the prevalence of nonalcoholic fatty liver disease decreased steadily as the serum bilirubin level increased. (47) Increased bilirubin appears to reduce early ischemia-reperfusion injury after liver transplantation. (48) Colorectal cancer risk was lowered by 25.7% per 1.0 mg/dL increase in total bilirubin. (49) Horsfall et al. found that mortality rates observed for people with hyperbilirubinemia in the general population were almost half compared to those of people without evidence of hyperbilirubinemia. (50) Furthermore, telomere length was increased in male individuals chronically exposed to increased unconjugated bilirubin, indicating a link between hyperbilirubinemia and longevity. (51) These observations indicate that in addition to the increased antioxidant capacity, hyperbilirubinemia has diverse beneficial impacts on human health (Fig. 2) .
MOLECULAR MECHANISM OF THE BILIRUBIN-MEDIATED ANTIOXIDATIVE EFFECT
The major antioxidative effect of bilirubin is derived from its chemical-reducing property. Based on its lipophilic properties, bilirubin is particularly effective at reducing lipophilic reactive oxygen species such as lipid peroxides and therefore effectively complements other, mainly hydrophilic antioxidants such as glutathione, vitamin C, and vitamin E. When bilirubin itself is oxidized by reactive oxygen species, it reverts back to its precursor, biliverdin, which is then recycled to bilirubin by biliverdin reductase at the expense of reduced nicotinamide adenine dinucleotide phosphate. This biliverdin-bilirubin redox cycle has been proposed to amplify antioxidant potency dramatically, (7) although its significance has also been questioned. (52) Elevation of serum bilirubin levels exerts a great impact on gene expression, (14) which may be associated with the beneficial effects of bilirubin.
Genetic and Epigenetic Factors Linked to Hyperbilirubinemia
UGT1
UGT1A1 belongs to the UGT1A subfamily of enzymes that are encoded by a single gene consisting of unique first exons and shared exons 2-5. Because UGT1A1 is the sole enzyme responsible for bilirubin glucuronidation, polymorphisms in the UGT1A1 gene that affect its function and activity most likely directly cause hyperbilirubinemia. So far, several genetic variants in the promoter region as well as in exon 1 and shared exons 2-5 have been identified (http://www. pharmacogenomics.pha.ulaval.ca/ugt-alleles-nomenclature). Among them, deleterious mutations that result in complete loss or severely reduced UGT1A1 activity cause the development of a rare and severe unconjugated hyperbilirubinemia called Crigler-Najjar syndrome types I and II. (53, 54) In this condition, significantly elevated serum bilirubin levels allow this compound to reach the brain, causing severe kernicterus. In addition, genetic variants resulting in only reduced UGT1A1 activity cause Gilbert syndrome, a benign condition characterized by moderately increased serum levels of unconjugated bilirubin, affecting up to 10% individuals in the general population. (55) Gilbert syndrome can be caused by several UGT1A1 variants; however, two major alleles observed in individuals with Gilbert syndrome are UGT1A1*6 and UGT1A1*28. The UGT1A1*6 (c.211G>A, p.Gly71Arg) allele, which is more frequent in Asian populations (10%-20%) but absent in Caucasians, has been associated with bilirubin levels in Chinese and Koreans. (56, 57) The most frequent functional UGT1A1 variant is a TA repeat polymorphism, varying in length from five to eight repeats located in the TATA box element of the UGT1A1 promoter region and impairing UGT1A1 transcription. The UGT1A1*28 allele, which contains seven repeats instead of six repeats in the reference allele UGT1A1*1, is the most frequent variant allele in different populations and was originally detected in an individual with Gilbert syndrome and mild unconjugated hyperbilirubinemia.
Not only might genetic variants in UGT1A1 alter hepatic expression of UGT1A1 but transcriptional regulation through epigenetic or transcription factors, or even posttranscriptional regulation, might also be linked to hyperbilirubinemia. Although posttranscriptional regulation of UGT1A expression through microRNAs has been investigated, (58) further studies are needed to examine the impact of microRNAs on the development of hyperbilirubinemia. In addition, tissue-specific and age-dependent expression of UGT1A1 is regulated by DNA methylation, (59, 60) and initial studies indicate an association of DNA methylation with bilirubin glucuronidation. (61) Whether aberrant hepatic DNA methylation is associated with hyperbilirubinemia needs further investigation in large population studies. Because severe neonatal hyperbilirubinemia and the onset of bilirubin encephalopathy result in part from delayed expression of UGT1A1 during development, factors regulating UGT1A1 expression might be important determinants as well. The UGT1A1 promoter region contains binding sites for nuclear receptors. As an example, the delayed expression of hepatic UGT1A1 has been associated with pregnane X receptor-mediated silencing of UGT1A1. (62) Moreover, a recent study demonstrated that deletion of the intestinal nuclear receptor corepressor 1, a regulator of epithelial cell maturation, completely reduces hyperbilirubinemia in humanized UGT1A mouse neonates due to intestinal UGT1A1 gene derepression. (63) 
GENETIC POLYMORPHISMS LINKED TO HYPERBILIRUBINEMIA AND THEIR BENEFICIAL IMPACT
Because bilirubin has antioxidant properties, mildly elevated bilirubin levels may have beneficial effects. Indeed, an association of the UGT1A1*28 polymorphism with a reduced risk of CVD was found. (45) However, independent studies could not confirm a link between genetically elevated bilirubin and risk of ischemic heart disease. (64) Moreover, increasing circulating unconjugated bilirubin was associated with a lower risk of respiratory disease and reduced incidence of lung cancer. (65) Furthermore, a protective role of the UGT1A1*28 allele against colorectal cancer has recently been reported, and patients with colorectal cancer had lower serum bilirubin levels compared to controls. (66) Patients carrying UGT1A1*28 showed reduced risk of head and neck cancers, (67) indicating that hyperbilirubinemia might be a suppressive factor against various types of cancer. However, there are also reports indicating that carriers of the UGT1A1*28 allele have a higher risk of developing colorectal and breast cancers. (68, 69) Taken together with the information in the previous section, it can be concluded that hyperbilirubinemia is beneficial for the prevention of various diseases such as CVD and cancer. However, there are several controversial reports that do not support the beneficial effect of bilirubin on diseases, (64, 68, 69) on the contrary suggesting that bilirubin may exert disadvantageous influences depending upon certain race, age, gender, or clinical conditions. Please see the Supporting Information.
Metabolomics in Hyperbilirubinemia Research and Future Direction
The beneficial effects of bilirubin are largely attributed to the antioxidative properties of the compound. In addition, there is increasing evidence that bilirubin modulates further metabolic pathways. For example, a proteomic approach carried out in a human neuroblastoma cell line revealed a protective function of the protein DJ-1 in the process of bilirubin-induced neurotoxicity, (70) indicating that cells exposed to bilirubin undergo an adaptive response wherein DJ-1 plays a crucial role in cellular oxidative stress homeostasis. In another study, in vitro analysis of human platelets treated with unconjugated bilirubin demonstrated thrombocytopenia induced by bilirubin through mitochondrial reactive oxygen speciesinduced p38 and p53 activation. The in vitro findings were confirmed by in vivo studies where a bilirubininduced alteration of apoptotic markers was observed. (71) Moreover, a mechanistic study of dietinduced obese mice has shown that bilirubin treatment regulates cholesterol metabolism, adipokines, and peroxisome proliferator-activated receptor c levels, which may positively affect insulin sensitivity and glucose tolerance. (72) Metabolomics reveals insight into hyperbilirubinemia as it enables a functional readout from the genome, epigenome, proteome, gut microbiome, and external perturbations such as drug treatment. (73) This signature of biochemical activity may uncover novel phenotypic factors involved in bilirubin homeostasis. For example, plasma analysis in infants with and without unconjugated hyperbilirubinemia revealed that levels of ornithine, aspartic acid, palmitoyl carnitine, and octadecadienoic acid carnitine contributed significantly to group separation of hyperbilirubinemic infants compared to controls. (74) These differences were also observed in the plasma of infants with biliary atresia and neonatal hepatitis syndrome, where increased conjugated bilirubin is observed, indicating that disruption of liver function might be attributed to those changes. In contrast, the strong contribution of ornithine to group separation was very specific to the plasma of unconjugated hyperbilirubinemia. Ornithine is an amino acid that exhibits antioxidant properties; therefore, unconjugated hyperbilirubinemia-affected ornithine might be involved in the beneficial effects of hyperbilirubinemia. In a study of 76 human subjects with and without hyperbilirubinemia, plasma samples were analyzed by 1 H nuclear magnetic resonance spectroscopy. (75) Among male subjects, plasma lysine and glucose levels were lower in those with hyperbilirubinemia compared to those in the control group. Among female subjects, metabolic analysis of plasma indicated that those who were hyperbilirubinemic exhibited lower valine, lysine, and glucose levels, while plasma acetone and citric acid levels were higher. This gender difference in plasma metabolic patterns may contribute to the higher risk of neonatal hyperbilirubinemia and kernicterus in male subjects.
In addition to metabolomics carried out on blood samples, further analyses of biological matrices such as tissue, urine, and feces will be pivotal in future studies to investigate the contribution of membrane transport processes as well as fecal and renal excretion of bilirubin and related compounds to the development of hyperbilirubinemia. For example, comprehensive tissue metabolomics analysis (76) carried out in liver, intestinal, or brain tissues will be required to assess the transport of bilirubin and its glucuronide in more detail. This is particularly important for samples derived from the small intestine, where detailed knowledge on corresponding transporters is still limited. With regard to urine, an inverse relationship between serum bilirubin level and excretion of bilirubin oxidative metabolites (biopyrrins) (77) was demonstrated in patients with Gilbert syndrome, illustrating the potential of urine metabolic analysis to assess elimination of bilirubin compounds from the body. Moreover, monitoring of urinary biopyrrin excretion may be used as a marker of oxidative stress and support future therapeutic strategies in hyperbilirubinemia research. Fecal analysis, carried out by either metabolomics or genomic techniques, will be required for better characterization of intestinal microflora and its impact on serum bilirubin levels. (78) Interestingly, recent data suggest that bilirubin itself modulates the function of enteric bacteria, indicating that heme metabolism may play a role in modulating bacterial function and survival. (79) Hence, an involvement of intestinal colonization in the pathogenesis of neonatal jaundice is conceivable. (80) Furthermore, in neonatal research, metabolomics analysis of breast milk components may identify further metabolites potentially involved in modulation of UGT1A1 activity or tissue-specific expression.
As outlined in the previous sections, although UGT1A1 plays a critical role in the development of hyperbilirubinemia, further genetic and epigenetic factors involved in heme catabolism or bilirubin membrane transport may contribute to serum bilirubin levels. Here, employing multi-omics approaches that enable parallel coverage of a broad spectrum of molecular species such as metabolites and proteins (81) or metabolites and transcripts (82) will allow exploration of crosstalk between different omics layers and possibly enable improved functional analysis of hyperbilirubinemia and its role in health and disease in the future.
Conclusions
Bilirubin has been recognized as a disadvantageous end product of heme catabolism due to its hydrophobic and neurotoxic properties. However, accumulating clinical observations indicate that hyperbilirubinemia brings various benefits to the human body (Fig. 2) . The beneficial effects are mostly caused by the antioxidant property of bilirubin, but recent studies further suggest the involvement of metabolic function and the immune system in the mechanism of the beneficial action of bilirubin. Given that infants whose serum bilirubin level was higher had a lower incidence of asthma in later periods of life, neonatal hyperbilirubinemia might support good health in later life. In that case, guidelines for the treatment of neonatal jaundice may be modified and breast-feeding may be more encouraged, though it must be recollected that bilirubininduced kernicterus is highly lethal. Further studies are needed to reveal the impact of long-term hyperbilirubinemia on human health and its underlying mechanism.
